Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
Other Sizes |
|
ln Vitro |
Macelignan (1-50 μM; 72 h) did not decrease cell viability on its own; rather, UVB therapy decreased HaCaT cell viability in a dose-dependent manner, reducing it by about 80 percent. The control value in percentage of hacat cells is 100 μM [1]. COX-2 expression is lowered by myristolignan (0.1–1 μM; 24 hours) in a concentration-dependent manner. In hacat cells, COX-2 expression is about 50% reduced at the maximum myristolignan concentration (1 μM)[1].
|
---|---|
ln Vivo |
Macelignan (oral; 15 mg/kg; once daily for three weeks) exhibits antidiabetic effects in vivo. There was no difference in baseline (day 0) fasting blood glucose levels between the groups; at the end of the experiment, the values in the Macelignan-treated group of C57BL/KsJ-db/db mice were significantly lower than those in the diabetic control group [2].
|
Cell Assay |
Cell viability assay [1]
Cell Types: Hacat Cell Tested Concentrations: 1 μM; 2.5 μM; 5 μM; 10 μM; 15 μM; 50 μM Incubation Duration: 72 hrs (hours) Experimental Results: Cell death was induced by UVB irradiation of 10 μM 30 mJ/cm2. Western Blot Analysis [1] Cell Types: Hacat Cell Tested Concentrations: 0.1 μM; 0.5 μM; 1 μM Incubation Duration: 24 hrs (hours) Experimental Results: UVB-induced COX-2 expression in cells was diminished. |
Animal Protocol |
Animal/Disease Models: Male C57BL/KsJ-db/db mice [2]
Doses: 15 mg/kg Route of Administration: po (po (oral gavage)) 15 mg/kg; one time/day for three weeks. Experimental Results: Dramatically diminished blood sugar levels in mice. |
References |
[1]. Anggakusuma, et al. Effects of macelignan isolated from Myristica fragrans Houtt. on UVB-induced matrix metalloproteinase-9 and cyclooxygenase-2 in HaCaT cells. J Dermatol Sci
[2]. Jiyoung Yeo, et al. Effects of a multi-herbal extract on type 2 diabetes. Chin Med. 2011 Mar 4;6:10. [3]. Chun-Ai Cui, et al. Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats. Neurosci Lett. 2008 Dec 19;448(1):110-4. |
Molecular Formula |
C20H24O4
|
---|---|
Molecular Weight |
328.4022
|
CAS # |
107534-93-0
|
SMILES |
O1C([H])([H])OC2C([H])=C([H])C(=C([H])C1=2)C([H])([H])[C@@]([H])(C([H])([H])[H])[C@@]([H])(C([H])([H])[H])C([H])([H])C1C([H])=C([H])C(=C(C=1[H])OC([H])([H])[H])O[H]
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
DMSO : ~100 mg/mL (~304.51 mM)
|
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (7.61 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (7.61 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.5 mg/mL (7.61 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 3.0451 mL | 15.2253 mL | 30.4507 mL | |
5 mM | 0.6090 mL | 3.0451 mL | 6.0901 mL | |
10 mM | 0.3045 mL | 1.5225 mL | 3.0451 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.